Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “rCDI”

12 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 12 results

Early research (Phase 1)Looking for participantsNCT05911997
What this trial is testing

MTC Versus FMT in for RCDI

Who this might be right for
Clostridiodies Difficile Infections
Icahn School of Medicine at Mount Sinai 60
Testing effectiveness (Phase 2)Study completedNCT03497806
What this trial is testing

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

Who this might be right for
Clostridium Difficile InfectionRecurrent Clostridium Difficile InfectionC. Diff+8 more
Finch Research and Development LLC. 132
Testing effectiveness (Phase 2)Study completedNCT02437487
What this trial is testing

SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)

Who this might be right for
Clostridium Difficile
Seres Therapeutics, Inc. 89
Testing effectiveness (Phase 2)Study completedNCT03110133
What this trial is testing

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff

Who this might be right for
Clostridium Difficile Infection Recurrence
Finch Research and Development LLC. 206
Large-scale testing (Phase 3)Study completedNCT03183141
What this trial is testing

ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection

Who this might be right for
Clostridioides Difficile Infection
Seres Therapeutics, Inc. 263
Not applicableNot Yet RecruitingNCT06992453
What this trial is testing

Multi-omics Dissection of Gut Microbiome Engraftment During FMT

Who this might be right for
Recurrent C. Difficile (rCDI)Ulcerative Colitis (UC)Metabolic Syndrome (MetS)
Catholic University of the Sacred Heart 90
Testing effectiveness (Phase 2)WithdrawnNCT04729790
What this trial is testing

Randomized Clinical Trial of Standard FMT Treatments

Who this might be right for
Clostridium Difficile
The University of Texas Health Science Center, Houston
Early research (Phase 1)UnknownNCT02399618
What this trial is testing

Freeze-dried, Capsulized FMT for RCDI

Who this might be right for
Clostridium Difficile Infection
Jinling Hospital, China 20
Large-scale testing (Phase 3)Looking for participantsNCT07458984
What this trial is testing

FMT Capsules for rCDI

Who this might be right for
Clostridioides Difficile Infection RecurrenceFMT
Helsinki University Central Hospital 76
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06948461
What this trial is testing

A Flexible Clinical Trial to Test if Freeze-dried Fecal Microbiota Therapy Helps Treat Diarrhea-predominant Irritable Bowel Syndrome or Prevent Recurring C. Difficile Infections.

Who this might be right for
Irritable Bowel Syndrome, Diarrhea-Predominant (IBS-D)Recurrent Clostridioides Difficile Infection (rCDI)Fecal Microbiota Therapy (FMT)+2 more
PharmaPlanter Technologies Inc 63
Not applicableWithdrawnNCT05606159
What this trial is testing

Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections

Who this might be right for
Clostridium Difficile Infection Recurrence
Novozymes A/S
Not applicableApproved For MarketingNCT02437500
What this trial is testing

Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)

Who this might be right for
Clostridioides Difficile Infection
Seres Therapeutics, Inc.